)
Shuji Sato
Vice President of Innovative Solutions,
Immunoprecise Antibodies
Shuji Sato, VP of Innovative Solutions at IPA, specializes in delivering advanced scientific services for complex projects. With 20+ years in R&D, he has led in vivo and in vitro antibody discovery teams in biotech, pharma, and academia. He applies his broad drug development expertise to drive innovative workflows.
Dr. Sato earned a PhD in Molecular Microbiology from Tufts University and trained at Harvard Medical School. He has held key roles at Cell Signaling Technology, Bluefin Biomedicine, Pfizer, and Dragonfly Therapeutics. His research career includes numerous peer-reviewed publications and patents.
Sessions
-
17-Jun-2024Poster Presentation: Maximizing VHH lead generation for therapeutic breakthroughs
-
28-Oct-2024Poster Presentation: Strategies to amplify the therapeutic potential of rabbit-derived antibodies
-
14-Apr-2025Sponsor-led Poster Presentation: Lead Identification & Optimization Topic: Integration of Rabbit Antibody Discovery with LENSai as a Comprehensive Solution for Therapeutics Generation